Inactive Instrument

Analyst Reco. Foamix Pharmaceuticals Ltd. Nasdaq

Equities

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	23-05-12	MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	23-03-14	MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	22-08-10	MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target	21-12-06	MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating	21-08-13	MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating	21-05-07	MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating	21-03-08	MT

No results for this search